WO2005120490A1 - 咀嚼に対して安定なカプセル - Google Patents
咀嚼に対して安定なカプセル Download PDFInfo
- Publication number
- WO2005120490A1 WO2005120490A1 PCT/JP2005/011092 JP2005011092W WO2005120490A1 WO 2005120490 A1 WO2005120490 A1 WO 2005120490A1 JP 2005011092 W JP2005011092 W JP 2005011092W WO 2005120490 A1 WO2005120490 A1 WO 2005120490A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- capsule
- soft
- thickness
- gelatin
- film
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a capsule containing a compound having an oral irritating property, but whose contents do not easily leak during chewing.
- compositions to be administered orally are usually first taken with water or the like, apart from special preparations such as tuple tablets and sublingual tablets.
- special preparations such as tuple tablets and sublingual tablets.
- the method of taking a pharmaceutical product is specific to each designed product based on the site of absorption of the active ingredient and the duration of the blood, so if the wrong method is taken, the desired effect cannot be obtained. Force May cause serious side effects. Therefore, medical institutions such as hospitals and pharmacies provide patients with guidance on how to take the correct dosage, but the results have not been satisfactory, and many patients still take the wrong dosage regimen.
- Soft capsules usually consist of a gelatin-based capsule shell filled with a liquid or suspended liquid. After taking the soft capsule, the capsule film breaks down quickly in the digestive tract, dispersing and dissolving the liquid content more quickly than tablets, so the dosage form is expected to be able to expect good absorption of the drug.
- preparations made to bring about the characteristics of this soft capsule have a thin capsule film in general because of the main purpose of easy disintegration in the digestive tract, and as described above, they can be chewed by mistake when taken. If the liquid is easily leaked into the mouth It has a title. In particular, when the content liquid is a substance with irritation, it causes unpleasant sensations such as edible taste, pain, and burning sensation in the oral cavity. Puser is not desirable for patients.
- pentanoic acid derivatives including (2R) -2-propy ⁇ / octanoic acid, which are effective as cerebral function improvers for various diseases because they have the function of improving the function of astrocytes.
- pentanoic acid derivatives are to be administered as a solid composition for oral administration such as tablets, pills, capsules, powders, granules and the like, and It is described that the capsules include hard capsules and soft capsules.
- (2R) -2-propyloctanoic acid is an extremely irritating substance, so when it is filled in a soft capsule of a general formulation and chewed, it easily leaks into the oral cavity and has an extremely strong ego taste. It turned out that I felt a burning sensation.
- (2R) — 2-Propyloctanoic acid is a substance that is expected to be administered to elderly patients because of its indications. For use in elderly patients who often make mistakes, chewing such a formulation that leaks out easily is not desirable.
- an object of the present invention is to provide a soft capsule which contains (2R) -2-propyloctanoic acid or a salt thereof and whose contents do not easily leak during chewing.
- the present inventors have conducted intensive studies in order to solve the above-mentioned problems.
- a soft capsule containing (2R) -2-propyloctanoic acid or a salt thereof was used by using a capsule film containing gelatin and glycerin.
- the capsule is provided with one or more properties selected from the following (A) to (F), preferably all of the properties, so that the capsule is easily disintegrated in the stomach and We succeeded in giving the feature that the contents do not leak easily during chewing.
- the present inventors have further studied based on this finding, and have shown that such means can be applied not only to (2R) _2-lipopirotatatanic acid or a salt thereof, but also to compounds having oral irritation in general.
- the present invention has been completed.
- the present invention relates to a chew-stabilizing capsule containing [1] (2R) -2-propyloctanoic acid or a salt thereof, and having the following characteristics of (1) and Z or (2): (1) (a) At least one capsule base selected from proteins, polysaccharides, biodegradable plastics, and hardened fats and oils (b) Contains a plasticizer and has a capsule coating with a water content of 4.0 to 10.0% (2) is easily broken in the stomach; [2] is a soft capsule, the mastication-stabilizing capsule according to the above [1]; [3] One or more selected from the following (A) to (F): The chew-stabilizing soft capsule according to the above [2] having the following characteristics: (A) shows a strength of 150 to 400 N in a crack load test; (B) says that the disintegration time in the crushing test method specified in the Pharmacopoeia of Japan is 3 (C) The thickness of the capsule film is 0.05-0.50 mm; (D) The thickness of the capsule film
- the crushing time is 5 to 8 minutes in the crushing test method specified in the Japanese Pharmacopoeia;
- the abdominal thickness of the capsule film is 0.10 to 0.45 mm;
- the first joint thickness of the capsule shell is 0.15 to 0.50 mm;
- the second joint thickness of the capsule shell is 0.10 to 0.40 mm;
- the moisture content of the capsule shell is 5.0 to 8.0%;
- the capsule base is gelatin,
- the method for stabilizing soft capsules for chewing characterized by imparting at least one property selected from the following (A) to (E):
- (A) The strength indicated by the crack load test is 150 to 4
- (B) The thickness of the abdomen of the capsule coating is 0.05 to 0.50 min;
- (C) The thickness of the first joint of the capsule coating is 0.10 to 0.55 ⁇ ;
- (D) The capsule coating The thickness of the second joint is 0.05 to 0.50 min;
- (B) The abdomen thickness of the capsule coating is 0.10-0.45 mm;
- (C) The first joint thickness of the capsule coating is 0.15-0.50 mm;
- (D) The capsule coating (E) the capsule coating has a water content of 5.0 to 8.0%; [23] contains a compound having
- (2R) -2-propyloctanoic acid has the formula (I)
- the salt of (2R) -2-propyloctanoic acid is preferably a pharmaceutically acceptable salt.
- the pharmaceutically acceptable salts are preferably non-toxic and water-soluble.
- Suitable salts of (2R) -2-propyloctanoic acid include, for example, salts with inorganic bases, salts with organic bases, salts with basic natural amino acids and the like.
- Examples of the salt with an inorganic base include an alkali metal salt (eg, sodium salt, potassium salt, lithium salt, etc.), an ammonium salt (eg, tetramethylammonium salt, tetrabutylammonium salt, etc.), etc. Is preferred.
- salts with an organic base examples include alkylamines (eg, methylamine, dimethylamine, trimethylamine, triethylamine, etc.), heterocyclic amines (eg, pyridine, picoline, piperidine, etc.), alkanolamines (eg, For example, ethanolamine, diethanolamine, triethanolamine, etc.), dicyclohexyl / amine, ⁇ , ⁇ , dibenzyl ⁇ / ethylenediamine, cyclopentylamine, benzylamine, phenethylamine, tris (hydroxymethamine).
- alkylamines eg, methylamine, dimethylamine, trimethylamine, triethylamine, etc.
- heterocyclic amines eg, pyridine, picoline, piperidine, etc.
- alkanolamines eg, For example, ethanolamine, diethanolamine, triethanolamine, etc.
- dicyclohexyl / amine
- the salt with a basic natural amino acid is not particularly limited as long as it is a salt with a basic amino acid which exists in nature and can be purified, and examples thereof include arginine, lysine, orditin, histidine and the like. Are preferred. Of these salts, preferred are, for example, alkali metal salts and basic natural amino acid salts, and particularly preferred are sodium salts.
- (2R) -1-propyloctanoic acid or a salt thereof can be prepared by a method known per se, for example, EP 0632008, WO 99/58513 pamphlet, WO 00/48982 pamphlet, Patent No. 3032447, Patent No. 3084345, WO 03/051852 pamphlet, WO 04/110972 pamphlet, etc., for example, Comprehensive Augag 'Transformation : Completion Guide 'Two Fanchonanole Gunorape Preparations, Second Edition (Richard C. Lalock, John Wiley and Sons Inc., 1999. 9) [Comprehensive Organic Transformations: A Guide to Functional Group Preparations , 2nd Edition (Richard C.
- the product of the reaction can be purified by conventional means of purification, for example, distillation under normal or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin layer chromatography, or Can be purified by column chromatography or a method such as washing and recrystallization. If desired, the composition may be subjected to a treatment such as freeze-drying.
- the (2R) -2-propyloctanoic acid or a salt thereof used in the present invention is not limited to a substance that is substantially pure and a single substance, but may be an impurity (for example, a by-product derived from a manufacturing process). , A solvent, a raw material, or a decomposed product) as long as the drug substance is within the permissible range.
- the content of impurities acceptable as APIs differs depending on whether (2R) -2-propyloctanoic acid is used or its salt, and also depending on the impurities contained.
- (2R) -2-propyloctanoic acid heavy metal is about 20 p or less, optical isomer S is about 1.49 mass% or less, residual solvent is 2-propanol or
- heptane is less than about 5000 ppm in total and moisture is less than about 0.2% by weight.
- (2R) -2-propyloctanoic acid or a salt thereof may be in any form.
- it may be a liquid or a solid, or a semi-solid having an appropriate fluidity (for example, a gel-like or wax-like solid).
- a solid can be used without any particular limitation, whether it is crystalline, non-crystalline (amorphous), or a mixture of any ratio thereof.
- it may be a liquid such as (2R) -2-propyloctanoic acid or a waxy solid such as (2R)-.
- 2-propyloctanoic acid 'sodium salt There may be.
- (2R) -2-propynoleoctanoic acid or a salt thereof is preferably (2R) -2-propyloctanoic acid and (2R) -2-propyloctanoic acid'sodium salt.
- (2R) -2-propyloctanoic acid is preferred.
- the chew-stabilizing capsule means a capsule whose contents do not easily leak during chewing. B Chewing includes intentional chewing and unintentional chewing, but the chew-stabilizing capsule of the present invention easily leaks the contents, particularly when the chewing is unintentional chewing. The effect that there is not can be shown more effectively.
- the capsule may be any capsule that is usually called by those skilled in the art.
- it may be a soft capsule as described in detail below, or a hard capsule or the like.
- soft capsules are preferred.
- the present invention will be disclosed using a soft capsule as an example.
- the chewing-stabilizing soft capsules containing (2R) -2-propyloctanoic acid or a salt thereof include (1) (a) ) Contains at least one capsule base selected from proteins, polysaccharides, biodegradable plastics and hardened fats and oils, and (b) a plasticizer. And / or 7 or (2) have the property of being easily ruptured in the stomach, and preferably have both properties.
- the characteristic (1) of the present invention relates to the composition of the capsule film.
- the capsule of the present invention is composed of a liquid content and a capsule membrane, like a general soft capsule.
- the capsule film contains (a) a force-pressel base material which is a main component of the capsule film, and (b) a plasticizer.
- a fragrance eg, heart oil, cinnamon oil, strawberry, etc.
- preservatives eg, ethyl parahydroxybenzoate, propyl parahydroxybenzoate
- pigments eg, yellow 4, yellow 5, red 3, blue 1, copper black
- opacifying agents eg, titanium dioxide, red iron oxide, iron sesquioxide, etc.
- solubility modifiers eg, cellulose acetate) Tetphthalate, alkali metal salt of hydroxypropylmethylcellulose, alkali metal salt of hydroxymethylcellulose acetate succinate, alkali metal salt of alginate, alkali metal salt of polyacrylate, methylcellulose, carboxymethylcellulose, casein, collagen, agar powder, polybutyl alcohol, Etc.
- a capsule coating contains water as a constituent component. The water content in the capsule coating is indicated using an index of water content, as
- the capsule base used in the capsule coating of the present invention may be any substance as long as it can be used as a base for the soft capsule coating.
- proteins eg, gelatin, gelatin hydrolyzate, collagen, collagen hydrolyzate, casein, etc.
- polysaccharides eg, starch, amylose, polygalaturonic acid, agar, carrageenan, gum arabic, dielan gum, xanthan gum, Pectin, alginic acid, etc.
- biodegradable plastics eg, polylactic acid, polyhydroxybutyric acid, polyglutamic acid, etc.
- hardened fats eg, triglycerides of medium-chain fatty acids ⁇ diglycerides (eg, butter, margarine, shortening, cocoa butter, etc.) ) Etc.
- triglycerides of medium-chain fatty acids ⁇ diglycerides eg, butter, margarine, shortening, cocoa butter, etc.
- capsule bases may be used in combination.
- proteins particularly gelatin
- gelatin can be any gelatin as long as it can be used as a base for a soft capsule film.
- alkali-treated gelatin acid-treated gelatin, peptide gelatin, low-molecular gelatin, gelatin derivatives, chemically modified gelatin, succinated gelatin and the like may be used.
- the origin is derived from various animals such as mammals (for example, sea lions, pigs, etc.), fishes (for example, tilapia, Thailand, tuna, catfish, etc.), and birds (for example, chickens, ostriches, etc.). Do not specifically limit gelatin Can be used well.
- the plasticizer used for the capsule coating of the present invention may be any substance as long as it can be used as a plasticizer for the soft capsule coating.
- sugars eg, sucrose, sucrose, water sugar, etc.
- sugar alcohols eg, sorbitol, xylitol, mannitol, etc.
- polyhydric alcohols eg, glycerin, ethylene glycolone, polyethylene glycolone, Propylene glycol
- More preferred are, for example, glycerin, sorbitol, polyethylene glycol and the like, among which glycerin and sorbitol, particularly glycerin are preferred.
- the glycerin may be any glycerin as long as it is generally referred to as glycerin, and is preferably, for example, glycerin or glycerin, and particularly preferably, is glycerin.
- the capsule film using gelatin as a capsule base is preferable as the capsenole film in the capsule of the present invention.
- a capsule film containing gelatin as a capsenole base and glycerin as a plasticizer is preferable.
- the strong capsule film may further contain sorbitol as a plasticizer if desired.
- the content of sorbitol is about 20 parts by mass with respect to 100 parts by mass of gelatin as a capsule base.
- the content of glycerin is preferably about 20 parts by mass or less based on 100 parts by mass of gelatin as a capsule base.
- the mixing ratio of the capsule base (particularly, gelatin) and glycerin is preferably about 25 to about 40 parts by weight of glycerin per 100 parts by weight of forcepsel base. Particularly preferred is about 30 parts by weight of glycerin per 100 parts by weight of forcepsel base.
- the characteristic (2) of the present invention relates to the decayability of the capsule.
- the collapse time of the force capsule, etc. the composition of the capsule coating may be adjusted as described above, or the thickness of the capsule coating or the moisture content of the capsule coating may be adjusted as described later.
- the capsule disintegration time required for imparting the above-mentioned property of being “gastric easily lyophilizable” to the capsule of the present invention is about 3 to about 10 minutes by a crushing test method, more preferably about 10 minutes. It is 5 to about 8 minutes, particularly preferably about 5.7 to about 6.3 minutes. Known methods can be used for the collapse test.
- a method commonly known as a capsule decay test method for capsules especially the decay test method listed in the pharmacopoeia of each country, especially the decay test method listed in the Japanese Pharmacopoeia, especially the Japanese Pharmacopoeia in the Fourteenth Edition It is preferable to use the disintegration test method described in the above.
- (2R)-Soft capsules containing 2-propyloctanoic acid or a salt thereof and exhibiting the above-mentioned decay time in the decay test method listed in the Japanese Pharmacopoeia have different values in any other decay test method. Even if shown, they are all included in the present invention.
- the property of (2) of the present invention that is, the property of “easy to break into the stomach”, does not change over time with storage of the capsule.
- dissolution of soft capsules is delayed depending on the components of the liquid contents and the film components as they are stored.
- the term “elution delay” means that the storage of soft force capsules causes some change in the force capsule film with the passage of time, and the disintegration and dissolution of the capsules deteriorate.
- soft capsules with delayed dissolution do not disintegrate or dissolve rapidly during ingestion, and thus may not be able to achieve desirable drug efficacy. Therefore, the property of (2) of the present invention, that is, the property of “easy to stomach rupture” does not cause or is unlikely to change over time, that is, does not cause so-called elution delay, or It is desirable that it does not easily occur.
- the degree of “elution delay” can be confirmed by storing the capsule of the present invention for an arbitrary period of time, subjecting the capsule to an elution test, and comparing with an initial value.
- the dissolution test can be performed by a known method. For example, in general, tablets and capsules Known as the dissolution test method for solid preparations for pharmaceutical use, especially the dissolution test method listed in the pharmacopoeias of each country, especially the dissolution test method listed in the Japanese Pharmacopoeia, especially the dissolution test method listed in the Japanese Pharmacopoeia 14th Edition It is preferable to carry out in accordance with the above.
- the initial value is substantially the time immediately after production (for example, immediately after production to within 10 days after production, etc., preferably immediately after production to within 5 days after production, and more preferably, immediately after production to within 3 days, etc.).
- the value obtained by subjecting the capsule to the above-mentioned dissolution test immediately after production particularly preferably within 24 hours or the like.
- the storage conditions for confirming the degree of “elution delay” are not particularly limited, but may be room temperature, for example, which is usually performed by those skilled in the art, or may be generally referred to as a harsh test. High temperature and / or high humidity conditions may be used. By using high-temperature and / or high-humidity conditions, long-term storage results at room temperature can be obtained in a shorter period of time.
- “reduced dissolution is reduced” means that the dissolution rate after storage for an arbitrary period does not substantially change from the initial value (dissolution rate) or the change rate is within 20%. It is preferably within 15%, more preferably within 10%.
- the conditions of the dissolution test for obtaining the rate of change must be the same for the sample before storage and the sample after storage for an arbitrary period.
- the initial value should also be determined by the dissolution test under the same conditions. It is necessary to use the value of the dissolution rate 30 minutes after the start of the test.
- the storage conditions and the length of the period for confirming the presence or absence of elution delay are not particularly limited, but the conditions reflecting storage at a hospital, pharmacy, patient home, or the like as a drug are preferred.
- storage at room temperature can be exemplified, and as one index, as described in the Examples below, at about 25 to about 30 ° C for about one and a half years (for example, about 16 to about 2 , For example, for about 17 to about 19 months).
- a fast-dissolving soft capsule refers to a soft capsule capable of releasing a liquid content in the capsule, in which the film breaks down immediately after taking the capsule.
- the degree of “quick solubility” of the fast-dissolving soft capsule can be determined by various dissolution test methods, for example, the method described in the Pharmacopoeia as described above (for example, the paddle method of the Japanese Pharmacopoeia dissolution test second method described in Examples below). Etc.).
- the fast-dissolving soft capsule containing (2R) -2-propyloctanoic acid or a salt thereof is a soft capsule containing (2R) -2-propyloctanoic acid or a salt thereof.
- Any material may be used as long as it exhibits the above-described fast-dissolving properties.
- the dissolution rate 30 minutes after the start of the test is about 60% or more (about 60 to about 100%), preferably about 80% or more (about 80 to 100%). About 100%), more preferably about 90% or more (about 90 to about 100%).
- (2R) Soft capsules containing 2-propyl octanoic acid or a salt thereof that meet this condition Everything is included in the fast-dissolving soft capsule of the present invention.
- the dissolution test may be performed at any time after the production of the soft capshenole, but it is preferable to measure the dissolution test substantially immediately after the production as described above, for example. By performing the dissolution test substantially immediately after the production, it is possible to accurately determine whether or not the soft force capsule has been produced as a fast-dissolving soft force capsule.
- the property of mastication stabilization relates to the strength, that is, the hardness of the capsule.
- the thickness of the capsule coating, the moisture content of the capsule coating, and the like may be adjusted.
- the capsule preferably has a strength of about 150 Newtons (hereinafter referred to as a crack load test). , N.) More preferably, it is about 150 to about 400N, particularly preferably about 180 to about 350N, particularly preferably about 193 to about 310N.
- the crack load test can be performed by a known method. More specifically, as shown in the examples described later, for example, the sample is measured using a pressurizing machine that can compress two samples from above and below using two parallel surfaces, such as a Shimadzu desktop bench tester (EZ Test-500N). be able to.
- a pressurizing machine that can compress two samples from above and below using two parallel surfaces, such as a Shimadzu desktop bench tester (EZ Test-500N). be able to.
- the capsule coating of the capsule of the present invention contains water in addition to the capsule base and the plasticizer, but by adjusting the water content in the forceps coating, that is, by adjusting the water content.
- the strength of the capsule of the present invention can be adjusted.
- the preferred moisture content of the capsule shell for imparting the above strength to the capsule of the present invention is about 5.0 to about 9.0%, more preferably about 5.0 to about 8.0%, and particularly preferably about 5.6 to about 7.3%.
- the water content of the capsule film can be measured by a known method.
- the preferable thickness of the capsule coating for imparting the strength to the force capsule of the present invention depends on which of the thickness of the abdomen, the thickness of the first joint, and the thickness of the second joint is measured. different.
- “abdomen”, “first joint”, and “second joint” are terms commonly used by those skilled in the art, but “abdomen” is used for filling the content liquid when molding forcepsels.
- the first part is the part where the film sheet joins first when forming the capsule, and the second part is the last part when the capsule is formed. It means the part where the coating sheet is joined.
- the film sheet refers to a sheet containing a component of a capsule film used in a method of manufacturing a soft capsule generally called a punching method such as a rotary die method.
- two coating sheets are formed with a die mouth that matches the shape of the soft force capsule, and then filled with the liquid content to form an arbitrary shape, for example, an oval type or round type.
- Soft capsules such as (round) type, suppository type, oblong type and tube type can be manufactured.
- each part of the capsule film can be measured by a known method.
- the center of the soft capsule is sliced using a sharp knife such as a scissor knife, and the liquid content is washed with an organic solvent (eg, n-hexane, ether, acetone, alternative chlorofluorocarbon, etc.) and the like.
- the measurement can be performed using a scale or the like while observing the cut surface with an optical microscope.
- the preferred capsule film thickness for imparting the above strength to the capsule of the present invention is about 0.05 to about 0.50 mm, more preferably about 0.10 to about 0.45 mm, particularly preferably about 0.14 to about 0.37 mm in abdominal thickness.
- mm about 0.10 to about 0.55 mm in the first joint thickness, more preferably about 0.15 to about 0.50 mm, particularly preferably about 0.18 to 0.42 mm, and about 0.05 to 0.50 mm in the second joint thickness.
- mm more preferably about 0.10 to about 0.40 mm, particularly preferably about 0.14 ⁇ 0.36mm.
- the strength of the capsule of the present invention is further improved by setting the thickness of any one of the abdomen, the first bonding portion, and the second bonding portion of the capsule coating within the above-mentioned range, and more preferably the entire thickness. be able to.
- the capsule is formed so that the thickness of the force capsule film and the moisture content of the force capsule film are respectively within the above ranges, and preferably both are within the above ranges.
- the strength described above can be imparted, and the capsule of the present invention can be provided as a chew-stabilizing capsule by imparting the above-mentioned property that "the contents do not easily leak during chewing".
- one of the preferred embodiments of the capsule of the present invention having both the characteristics (1) and (2) is a soft capsule containing (2R) -2-propyloctanoic acid.
- Such soft capsules show a decay time of about 5 to about 8 minutes in the decay test specified in the Japanese Pharmacopoeia, so that the contents do not easily leak during chewing and easily disintegrate in the stomach. It is a soft capsule that has the characteristic of being lipophilic, and satisfies all the objects of the present invention.
- the capsule of the present invention can be produced according to a known method for producing a soft capsule. Specifically, (1) a content solution containing (2R) -2-propyloctanoic acid or a salt thereof and (2) a solution for a film are prepared, and the thickness of the capsene film is reduced.
- a punching method for example, a punching method (for example, such as, for example, a punching method (for example, such as, for example, a punching method) so that the moisture content of the capsule coating falls within the above range, and the crushing time and strength are within the above ranges. , Rotary die method, etc.). can do.
- the coating solution contains a component that forms the composition of the capsule coating described above, and can be formed into a thin coating (corresponding to the coating sheet described above) in a force-melted state or a solution state.
- a coating solution can be prepared by mixing an appropriate amount of water (for example, purified water or the like) with the above-mentioned capsule base and plasticizer.
- a heating operation may be performed, if desired.
- the content liquid containing (2R) -2-propyloctanoic acid or a salt thereof can be prepared using (2R) -2-propyloctanoic acid or a salt thereof.
- the liquid content has appropriate fluidity (for example, fluidity that can be injected using a soft capsule filling machine (for example, fluidity with a viscosity of about 50,000 millipass-force (mPa ⁇ s) or less).
- mPa ⁇ s) or less millipass-force
- the method for preparing the content liquid can be appropriately changed depending on whether (2R) -2-propyloctanoic acid or a salt thereof is a solid liquid or a semisolid.
- (2R) -12-propylotatanic acid or a salt thereof is a liquid, it may be used as it is, or may be used by adding an appropriate additive as needed. Also, it can be used by mixing with oils and fats.
- fats and oils include medium chain fatty acids [eg, vegetable oils (eg, soybean oil, cottonseed oil, safflower oil, corn oil, olive oil, coconut oil, perilla oil, perilla oil, etc.), fish oils (eg, cod liver oil, etc.) Etc.), medium-chain triglycerides (MCT) [for example, Panassate (trade name, manufactured by Nippon Oil & Fats Co., Ltd.), ODO (trade name, manufactured by Nisshin Oil Co., Ltd.), etc.], and chemically synthesized tridalicerides [For example, 2-linoleoyl-1,3-dioctanoylglycerol (8L8), Triglycerides of a known composition such as 2-l
- additives used in soft capsule formulations and oral solutions eg, preservatives, preservatives, surfactants, solubilizers, emulsifiers, solvents, pH regulators, buffers, suspending agents, thickeners, stable And solubilizers
- preservatives and preservatives include benzoic acid, sodium benzoate, sodium sorbate, parabens (for example, ethyl para-hydroxybenzoate, butyl para-oxybenzoate, propyl para-oxybenzoate, etc.).
- surfactants examples include hydroxypropylmethylcellulose, polyvinylpyrrolidone, sucrose fatty acid esters, polyoxyethylene hydrogenated castor oils, polysorbate 80, polyethylene glycol, glycerin, and ethanol. , Propylene glycol, water (eg, purified water, distilled water for injection, etc.).
- PH adjusters and buffers include, for example, bases such as inorganic acids or alkalis, such as hydrochloric acid, sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate and the like; and organic acids such as citric acid, malic acid And tartaric acid or succinic acid or salts thereof.
- Adjustment of H may be performed according to a method for adjusting PH generally used in the technical field of oral liquid preparations or a method analogous thereto.
- Suspending agents and thickening agents include, for example, gum arabic, crystalline cellulose, veegum, xanthan gum, gelatin, metronose, edible salts thereof, carmellose, edible salts thereof and the like.
- examples of the stabilizer include an edible acid edible salt, an edible salt of sodium chloride, and a pyrosulfite.
- Solubilizers include, for example, cyclodexto Examples include phosphorus and arginine. These additives are generally blended in a ratio usually used for a formulation for oral administration.
- additives known in the art such as, for example, those described in Yakuji Nippo, 2000, “Drug Additive Dictionary” (edited by the Japan Pharmaceutical Excipients Association) may be used.
- (2R) -2-propyloctanoic acid or a salt thereof is solid
- a suitable solvent for example, water (eg, distilled water for injection, It can be used as a content liquid by dissolving, suspending, or emulsifying in purified water or the like), the medium-chain fatty acid, or the medium-chain fatty acid tridaliceride.
- the additive include the above-mentioned additives generally used for oral preparations. These additives can be added in combination of two or more components, if desired.
- (2R) -2-propyloctanoic acid or a salt thereof when semi-solid, it may be used as it is as a liquid in the same manner as in the case of a liquid, or a suitable additive may be added if desired. May be used. Also, as in the case of a solid, it can be used as a content solution by dissolving, suspending, or emulsifying in a suitable solvent in the presence or absence of a suitable additive. The same additives and solvents as described above may be used for converting the semisolid into a liquid content.
- One of the preferred contents in the present invention is a solution containing (2R) -2-propyloctanoic acid.
- (2R) -12-propyloctanoic acid is a liquid, it is particularly preferable to use it as a content liquid as it is. Further, for example, it is also preferable to use a mixture with the above-mentioned fats and oils.
- (2R) -2-propyloctanoic acid is a liquid (oil)
- it can be used as an aqueous content liquid by adding an appropriate additive.
- Preferred additives for use as an aqueous content liquid include, for example, water Examples thereof include a metal compound showing basicity in a solution.
- the metal compound which shows basicity in an aqueous solution is not particularly limited.
- a weak acid for example, phosphoric acid, carbonic acid, boric acid, sulfurous acid, organic sulfonic acid, an organic carboxylic acid having 2 to 6 carbon atoms (for example, 1 to 3
- Metal salts e.g., monovalent aliphatic monocarboxylic acids, dicarboxylic acids or tricarboxylic acids, etc.
- Alkali metal salts eg, sodium salt, potassium salt, lithium salt, rubidium salt, cesium salt, francium salt, etc.
- metal hydroxides eg, monovalent alkali metal hydroxides (eg, hydroxide) Sodium, hydroxylating water, lithium hydroxide, rubidium hydroxide, cesium hydroxide, francium hydroxide, etc.
- metal compounds may be used in combination of two or more components, if desired.
- (2R) -2-propyloctanoic acid can be used as an aqueous content liquid in the capsule of the present invention by mixing with these metal compounds and, if desired, further mixing water.
- the capsule may be dried by any method as long as it can be dried while maintaining the shape of the squeezed capsule, but a method using a combination of tumbler drying and shelf drying is preferably used. By performing these two drying steps, a uniform soft capsule of the present invention having a stable shape can be produced.
- the capsules before being subjected to the drying step may be referred to as “live cells” to distinguish them from the capsules after drying.
- Tumble drying is at about 15 to about 40 ° C, preferably about 20 to about 35 ° C, particularly preferably about 23 to about 30 ° C, for several hours to several days, preferably about 0 ° C.
- the reaction is carried out for 5 hours to about 1 day, more preferably for about 1 to about 12 hours, particularly preferably for about 1.5 to about 6 hours.
- Shelf drying is carried out at about 10 to about 40 ° C, preferably about 15 to about 35 ° C (: particularly preferably at about 20 to about 30 ° C, for several hours to several days, Is between about 6 hours and about 40, More preferably, it takes about 12 hours to about 3 days, particularly preferably about 1 to about 2 days.
- each capsule contains about 30 to about 600 mg, more preferably about 50 to about 400 mg, particularly preferably about 100 to about 30 Omg of (2R) -2-propyloctanoic acid or a salt thereof.
- Soft capsule In particular, soft capsules containing about 10 Omg or about 30 Omg of (2R) -2-propylotatanic acid or a salt thereof per capsule are preferred.
- the capsule of the present invention may be optionally packaged as desired.
- a package may be, for example, a non-unit package that is not individually packaged (eg, Balta package).
- a hermetically sealed package such as a so-called heat seal, in which a drug is sealed with a heat-adhesive film, may be used.
- the sealed packaging in the present invention includes, for example, packaging using “airtight containers” and “sealed containers” prescribed in the Pharmacopoeia.
- the heat seal includes PTP (Press Through Pack) packaging and SP (Strip Package) packaging, but PTP packaging is particularly preferred.
- the material of the PTP package examples include PVC (polyvinyl chloride), PVDC (polyvinylidene-mouth), coated PVC (polyvinyl chloride), PP (polypropylene), and polypropylene-based multilayer.
- the PTP packaging is preferably used together with the aluminum packaging.
- the capsule of the present invention may be subjected to PTP packaging or SP packaging, and then subjected to secondary packaging (so-called “pillow-wrap packaging”) of a certain quantity of the capsule with polyethylene or aluminum foil.
- Honraku's capsules such as “stomach friability” and “the contents do not leak out easily during chewing”, are instead of (2R) -2-propyloctanoic acid or its salt.
- the compound having oral irritation is used as the content liquid It is also applicable to cases where
- the compound having oral irritation is not particularly limited as long as it gives a discomfort (for example, edami taste, pain, bitterness, burning sensation, etc.) when the compound is taken into the oral cavity. Whether or not to cause discomfort in the oral cavity can be easily determined by performing a known test generally called a sensory test.
- Examples of the compound having oral irritation include, for example, L-tributophan, L-methyoyun, L-lysine, L-leucine, azithromycin, aminovirine, aminophylline, erythromycin, casein, caffeine, clarithromycin, chloramuecole , Gentian, saponin, digitoxin, cyclandate, snorepilin, cephalexin, assembly, tannin, tetracycline, calcium pantothenate, phenobarbital, oxosapium iodide, limonene, recinamine, potassium chloride, berberine chloride, hydrochloric acid Zelastine, Aminoguanidine hydrochloride, Echirefrine hydrochloride, Kiene hydrochloride, Diltiazem hydrochloride, Cefotiam hexetyl hydrochloride, Cefquinel daloxate hydrochloride, Tarampicillin hydrochloride Ticlovid
- the filling of the capsule with the compound having oral irritation may be carried out in accordance with the above-mentioned case of (2R) -2-propyloctanoic acid or a salt thereof.
- the soft capsule containing an orally irritating compound as an active ingredient which is produced by the same method as described above, is the same as the soft capsule containing (2R) -2-propyloctanoic acid or a salt thereof.
- Soft capsule that is easily broken in the stomach and stable to chewing, that is, the contents do not leak easily during chewing. It is.
- the characteristics of the capsule of the present invention provided in the form of soft capsules that is, the characteristics of "easy disintegration in the stomach" and “the contents do not easily leak during chewing” are as follows. This is applicable even when hard capsules are filled with, (2R) -2-propyloctanoic acid or a salt thereof.
- Hard capsules usually consist of two parts, a cap and a body, which are filled with a pharmaceutical ingredient.
- the crack load test is about 150 as in the case of the soft capsules described above.
- -Ton hereinafter abbreviated as N
- Such hard capsules may be manufactured so as to exhibit a crushing time of about 3 to about 10 minutes, more preferably about 5 to about 8 minutes, particularly preferably about 5.7 to about 6.3 minutes in the crushing test method. .
- the production of the hard capsule may be performed according to a known method (for example, an auger set, a press type, a press type, a disk type, etc.). Also, when using liquid material as the contents, seal the fitting part separately or take measures to lock when fitting so that there is no liquid leakage from the fitting part between the cap and the body. Is preferred.
- the capsule of the present invention contains (2R) -2-propyloctanoic acid or a salt thereof as an active ingredient, it can be used in mammals (for example, humans, non-human animals, for example, monkeys, hidge, Is useful for the prevention, treatment, and inhibition of Z or symptom progression, for example, in neurodegenerative diseases, neuropathies, or diseases requiring nerve regeneration in rats, mice, dogs, cats, cats, rats, mice, etc. .
- neurodegenerative disease encompasses all diseases involving degeneration of nerve cells, It is not limited by its etiology.
- the neurodegenerative disease according to the present invention includes a neuropathy and a disease requiring nerve regeneration.
- the nerve cells may be any nerve cells in the living body, such as the central nervous system (eg, cranial nerve, spinal nerve, etc.), and the peripheral nerves (eg, autonomic nervous system (eg, sympathetic nerve, parasympathetic nerve, etc.) ) Etc.).
- the neurodegenerative disease is, for example, a disease of the central nervous system, for example, Parkinson's disease, Parkinson's syndrome, Alzheimer's disease, Down's syndrome, amyotrophic lateral sclerosis, familial amyotrophic lateral sclerosis, progression Supranuclear palsy, Huntington's disease, spinocerebellar ataxia, dentate nucleus pallidum pallidal atrophy, oliveib cerebellar atrophy, cortical basal ganglia degeneration, familial dementia, frontotemporal dementia, Senile dementia, diffuse Lewy body disease, striatum-substantia nigra degenerative disease, chorea-ataxia, dystoia, Mage syndrome, cerebellar cortical atrophy, familial spastic paraplegia, motor nerve Disease, Matsucardo-Joseph's disease, Pick's disease, stroke (eg, cerebral hemorrhage (eg, hypertensive intracerebral hemorrr)
- Neuropathy includes all neurological disorders. That is, neuropathy includes those generally recognized as symptoms at the time of disease. For example, in Parkinson's disease or Parkinson's syndrome, tremor, muscle rigidity (rigidity), slow motion, postural reflex disorder, autonomic nervous disorder, lunging phenomenon, walking disorder, mental symptoms, etc. For example, in Alzheimer's disease, symptoms of dementia are included.For example, in amyotrophic lateral sclerosis or familial amyotrophic lateral sclerosis, muscular atrophy, muscle weakness, upper limb dysfunction Gait disorders, dysarthria, dysphagia, respiratory disorders, etc.
- the disease requiring nerve regeneration means a disease in which the absolute number of nerve cells is reduced due to the loss of nerve cells, and normal nerve function is impaired.
- diseases include the surgical implantation of cells that can form normal nerves (eg, neural stem cells, neural progenitor cells, neural cells, other stem cells, glial cells, etc.)
- the treatment that activates the cells and regenerates the nerves is performed.
- the capsule of the present invention can promote nerve regeneration by temporary or continuous administration when transplanting the above cells or activating endogenous cells.
- the capsule of the present invention is also useful as a nerve regeneration promoter or an S100 increase inhibitor.
- the capsule of the present invention is orally administered to a living body for the purpose of preventing, treating, and / or suppressing the progress of symptoms of the above-mentioned diseases.
- "prevention" means to prevent the establishment of the disease itself,
- Treatment refers to guiding the condition toward a cure
- suppression of symptom progression refers to suppressing the progression of the condition and stopping the progress.
- the dosage of the capsule of the present invention may vary depending on the degree of symptoms; age, sex, body weight of administration subject, timing of administration, interval; type of active ingredient, and is not particularly limited.
- Parkinson's disease When administered orally as a therapeutic agent for neurodegenerative diseases such as Parkinson's syndrome, Alzheimer's disease, amyotrophic lateral sclerosis, and familial amyotrophic lateral sclerosis, (2R) -2-propyloctanoic acid
- the active ingredient is a capsule containing a daily dose of about 50 to about 5000 mg, more preferably about 100 to about 1200 mg of a cap containing (2R) -2-propyloctanoic acid
- the cells are administered.
- drugs to be used in combination with the capsule of the present invention include, for example, antiepileptic drugs (for example, phenenorubbital, mehobarbital, metalbital, primidone, feetoin, etotoin, trimetadione, ethosuximide, acetyl funetride, carbamazepine, acetamazolamide) , Diazepam, sodium valproate, etc.), acetylcholinesterase inhibitors (eg, donevezil hydrochloride, TAK-147, rivastigmine, galantamine, etc.), neurotrophic factors (eg, ABS-205, etc.), aldose reduction Enzyme inhibitors, antithrombotics (eg, t-PA, heparin, etc.), oral anticoagulants (eg, perfurin, etc.), synthetic antithrombin drugs (eg, gabexate mesylate, naf
- J3 amyloid protein aggregation inhibitor for example, 007000703, ALZHEMED (NC-531), PPI-368 (Tokuhei 11-514333), PPI-558 (Tokuhei 2001-500852), SKF-74652 ( Biochem.
- brain function stimulants eg, aniracetam, yusergoline, etc.
- dopamine receptor agonists eg, L-dopa, promocribten, pergo Ride, Talidexol, Prasixoxol, Powerbergorin, Amantadine, etc.
- Monoamine oxidase (MAO) inhibitors eg, Safrazine, Depreunole, Senoresillin (Selegiline), Remacemide, Rinolezonole (riluzole), etc.
- Anticholinergics eg, trihexyphenezil, biperiden, etc.
- COMT inhibitors eg, entakapon, etc.
- therapeutic drugs for amyotrophic lateral sclerosis eg, rilzozo
- statin hyperlipidemia drugs eg, pravastatin sodium, atomatopasatin, simpastatin, rospastatin, etc.
- fibrate hyperlipidemia drugs eg, clofibrate, etc.
- Apoptosis inhibitors eg, CPI-1189, IDN-6556, CEP-1347, etc.
- nerve differentiation / regeneration promoters eg, leteprinim (Leteprinim), xaliproden (XaliDroden; SR-57746-A), SB-216763, etc.
- Non- Loid anti-inflammatory drugs eg, meloxicam, teoxicam, indomethacin, ibuprofen, cele
- nicotine receptor modulators gamma secretase inhibitors, amyloid vaccines, amyloid degrading enzymes, squalene synthase inhibitors, drugs for abnormal behavior and wandering associated with the progression of dementia, antihypertensive drugs, drugs for diabetes , Antidepressants, anxiolytics, disease-modifying antirheumatic drugs, anti-cytokine drugs (eg, TNF inhibitors, ⁇ ⁇ kinase inhibitors, etc.), parathyroid hormone ( ⁇ ⁇ ⁇ ), calcium receptor antagonists, etc. Is mentioned.
- the above concomitant drugs are examples, and the present invention is not limited to these.
- the administration method of these drugs used in combination is not particularly limited, and may be oral administration or parenteral administration. These drugs may be administered in combination of two or more.
- the concomitant drugs include not only those that have been discovered to date but also those that will be discovered in the future based on the mechanism described above.
- the soft capsule containing (2R) -2-propyloctanoic acid or a salt thereof according to the present invention has very low toxicity and can be judged to be sufficiently safe for use as a medicament.
- a compound having oral irritation particularly (2R) -2-propyloctanoic acid or a salt thereof, which is useful as an agent for preventing, treating and / or suppressing the progression of various diseases such as neurodegenerative diseases.
- Soft capsules can be provided. Such soft capsules are easily disintegratable in the stomach and It has the property that contents do not leak easily, so even if the elderly etc. chew by mistake while taking it, they can safely feel edami, pain, burning, etc. in the oral cavity It is an excellent pharmaceutical formulation that can be taken and can be rapidly absorbed and show pharmacological effects.
- the soft capsules provided by the present invention can withstand long-term storage without delaying elution, and can be provided to clinical sites as soft force capsules having excellent quality.
- the resulting raw spheres by sequentially subjecting the tumbler drying (24 ° C, 3 hours) and shelving dried (between hours 29 ° C S 15 to 45), the 300 meters g per capsule (2R) - 2- Soft capsules (2100 capsules) containing propyl octanoic acid were obtained. Further, the same operation was performed six times to obtain a total of seven lots of soft capsules. The shelf drying time for each lot was 27 hours for lots # 1 to # 5, 15 hours for lot # 6, and 45 hours for lot # 7.
- Table 1 shows the results of soft capsules containing (2R) -2-propyloctanoic acid (300 mg) produced using Pgelatin
- Table 2 shows the results of MCT-containing soft capsules produced in the same manner
- Table 3 shows the results of the obtained (2R) -2-propyloctanoic acid (100 mg) -containing soft capsules and MCT-containing soft capsules produced in the same manner
- Table 4 shows the results of the soft capsules produced using pepta gelatin.
- “Active” indicates that the capsule is a soft liquid containing (2R) -2-propyloctanoic acid as a liquid content
- MCT indicates that the soft liquid contains MCT as a liquid liquid. It is meant to be a Pexel.
- Soft capsules containing (2R) -2-propyloctanoic acid (300 mg) manufactured using ⁇ ⁇ ⁇ ⁇ gelatin have abdominal thickness force S0.145-0.320 mm, first joint thickness force S0.183-0.411 mm, and The joint thickness was 0.140-0.300 mm.
- the MCT-containing soft capsule produced in the same manner had an abdominal thickness of 0.160 to 0.333 mm, a first joint thickness of 0.224 to 0.452 mm, and a second joint thickness of 0.156 to 0.303 mm.
- the soft capsules containing MCT manufactured in the same way have abdominal thickness of 0.248- 0.388Mm s first bonding section thickness 0.204 ⁇ 0.400Mm, second joint portion had a thickness of 0.230 ⁇ 0.306nmi.
- Soft capsules containing (2R) -2-propyloctanoic acid (300 mg) manufactured using porcine gelatin have an abdominal thickness of 0.157 to 0.205 mm, a first joint thickness of 0.222 to 0.294 mm, and a second joint.
- the thickness force was 0.154 to 0.179 mm.
- the MCT-containing soft capsules produced in the same manner had an abdominal thickness of 0.193 to 0.212 mm, a first joint thickness of 0.268 to 0.329 mm, and a second joint thickness of 0.173 to 0.198 mm.
- the soft capsule containing (2R) -2-propyloctanoic acid (100mg) manufactured using porcine gelatin has abdominal thickness of 0.212 ⁇ 0.243mm, first joint thickness i ⁇ 0.208 ⁇ 0.235mm, second joint The part thickness was 0.237 to 0.257 mm.
- the soft capsule containing MCT manufactured in the same way has an abdominal thickness of 0.213 to 0.275 mm s, the first joint thickness force S0.187 to 0.243 mm, and the second joint thickness force S0.241 to 0.298 mm there were.
- Example 4 Measurement of water content of capsule film of soft capsule containing (2R) -2-propyloctanoic acid
- Example 2 Contains (2R) -2-propyloctanoic acid prepared in Example 1 and Example 2.
- the moisture content of the capsule coating was measured by the following method for the soft capsules having MCTs and the MCT-containing soft capsules similarly manufactured using MCT instead of (2R) -2-propyloctanoic acid.
- Table 5 shows the results of soft capsules containing (2R) -2-propyloctanoic acid (300 mg) manufactured using Pgelatin, and Table 6 shows the results of soft capsules containing MCT manufactured in the same manner.
- Table 7 shows the results of the soft capsule containing 2R) -2-propyloctanoic acid (100 mg) and the soft capsule containing MCT produced similarly, and Table 8 shows the result of the soft capsule produced using porcine gelatin.
- “ActiveJ indicates a soft capsule containing (2R) -2-propyloctanoic acid as a content solution
- “ MCT ” indicates a soft capsule containing MCT as a content solution. It means that.
- Table 5 shows the results of soft capsules containing (2R) -2-propyloctanoic acid (300 mg) manufactured using Pgelatin
- Table 6 shows the results of soft capsules containing MCT manufactured in the same manner.
- Table 7 shows the results of the soft capsule containing 2R) -2-propyloct
- the (2R) -2-propyloctanoic acid-containing soft capsules produced in Examples 1 and 2 and the MCT-containing soft capsules similarly produced by using MCT instead of (2R) -2-propyloctanoic acid were as follows.
- the strength (crack load) of the capsule was measured according to the method described in (1).
- Table 9 shows the results of soft capsules containing (2R) -2-propyloctanoic acid (300 mg) manufactured using Pgelatin, and Table 10 shows the results of soft capsules containing MCT manufactured in the same manner.
- Table 11 shows the results of soft capsules containing 2R) -2-propyloctanoic acid (100 mg) and MCT containing soft capsules produced in the same manner, and Table 12 shows the results of soft capsules produced using putagelatin.
- “Active” is a soft capsule containing (2R) -2-propyloctanoic acid as a content liquid
- MCT is a soft capsule containing MCT as a content liquid. It means something.
- the soft capsule containing (2R) -2-propyloctanoic acid (100 mg) manufactured using septum gelatin had a strength of 235.1N. Also made in the same way The soft capsule made had a strength of 274.7N
- Example 6 Measurement of collapse time of soft capsule containing (2R) -2-propyloctanoic acid
- the (2R) -2-propyloctanoic acid-containing soft capsules prepared in Examples 1 and 2 and the MCT-containing soft capsules similarly prepared using MCT instead of (2R) -2-propyloctanoic acid were The disintegration time of the capsules was measured for each of the 6 lots in accordance with the disintegration test method (capsules) described in the Japanese Pharmacopoeia XIV, and the mean value (Mean) was calculated.
- Table 13 shows the results of soft capsules containing (2R) -2-propyloctanoic acid (300 mg) manufactured using Pgelatin, and Table 14 shows the results of MCT-containing soft capsules manufactured similarly.
- Table 15 shows the results of soft capsules containing (2R) -2-propyloctanoic acid (100 mg) and MCT-containing soft capsules produced similarly, and Table 16 shows the results of soft capsules produced using porcine gelatin.
- “Active” indicates that the soft capsule contains (2R) -2-propyl octanoic acid as the content liquid
- MCTJ indicates that the soft capsule contains MCT as the content liquid. It means something.
- Soft capsules containing (2R) -2-propyloctanoic acid (100 mg) produced using septum gelatin had a disintegration time of 6.2 minutes. In addition, the disintegration time of the MCT-containing soft capsule produced in the same manner was 7.2 minutes.
- Example 7 Crushing test of soft capsules containing (2R) -2-propyloctanoic acid
- Table 17 shows the results of the soft capsules manufactured using Pashi gelatin
- Table 18 shows the results of the soft capsules manufactured using ptaselatin.
- “Active” indicates a soft capsule containing (2R) -2-propyloctanoic acid as a liquid content
- “MCT” indicates a soft capsule containing MCT as a liquid content. It is meant to be a soft capsule containing
- Example 8 Evaluation test of dissolution delay of soft capsule containing (2R) -2-propyloctanoic acid
- the obtained fresh spheres were sequentially subjected to tumbling (23 ° C, 3 hours) and shelf drying (30 ° C, 27 hours) to give 300 mg of (2R) -2-propyloctane per capsule.
- the title soft force capsule containing the acid (2800 capsules) was obtained.
- This solution and (2R) -2-propyloctanoic acid (6.4 kg) are put into a soft capsule filling machine (rotary soft capsule molding machine H-1 type: Riki Mata), and (2R) -2-propyloctanoic acid is added.
- Fresh spheres of the filled soft capsule were obtained.
- the obtained fresh spheres were sequentially subjected to tumbling (24.5 ° C, 6 hours) and shelf drying (30 ° C, 18 hours) to obtain 100 mg of (2R) -2-propyloctanoic acid in one capsule.
- the resulting soft capsule (58800 capsules) was obtained.
- Test solution 0.05mo1 / L disodium hydrogen phosphate ⁇ O.OSSmo1 / L Phosphate buffer
- Liquid volume 900 mL
- the following table shows the results of the dissolution test (dissolution rate (%)) of soft capsules manufactured using Formulations 1A to 5A (300mg formulation) and Formulations 1B to 4B (100mg formulation). 19 and Table 20.
- Formulations 1A, 2A, 3A, 4A, and 5A exhibited dissolution rates of 100.0%, 99.6%, 99.6%, 99.5%, and 99.4%, respectively, 30 minutes after the start of the dissolution test. Also, Formulations 1B, 2B, 3B and 4B showed dissolution rates of 95.9%, 99.4%, 98.1% and 98.7%, respectively, 30 minutes after the start of the test.
- the soft capsules manufactured with Formulations 1A to 5A (300 mg formulation) and Formulations 1B to 4B (100 mg formulation) were all quick-dissolving soft capsules.
- the soft capsules manufactured with Formulations 2A to 5A (300 mg formulation) and Formulations 2B to 4B (100 mg formulation) were subjected to a dissolution test after a severe test.
- the results (elution rate (%)) are shown in Tables 21 and 22 below. Shown in As a guideline for the initial value, the initial value of prescription 3A for the 300 mg product and the initial value of recipe 3B for the 100 mg product are shown in the same table.
- the numerical value in parentheses below the elution rate after 30 minutes indicates the rate of change (%) from the initial value of each formulation.
- Formulation 2A dissolution tests were not performed because capsules cracked during the harsh test.
- Formulations 3A, 4A, and 5A showed 92.8%, 88.0%, and 34.4% dissolution rates 30 minutes after the start of the test, respectively.
- Formulations 2B, 3B, and 4B each were 98.2 ° / 30 minutes after the start of the test. , 90.7% and 91.4%.
- Formula 2A was not able to withstand the harsh test, and Formula 5A showed delayed elution.
- Table 23 shows the results of the dissolution test (dissolution rate (%)) of the soft capsules manufactured with Formulations 1A and 4A (300 mg M and Formulations 1B and 3B (100 mg formulation)) after the long-term stability test. The results are shown in Table 24. The numerical values in parentheses below the dissolution rate after 30 minutes indicate the rate of change (%) from the initial value of each formulation.
- Formulations 1A and 4A showed dissolution rates of 71.5% and 95.3%, respectively, 30 minutes after the start of the test.
- Formulations 1B and 3B showed dissolution rates of 93.3% and 95.4%, respectively, 30 minutes after the start of the test.
- Formulation 1A showed delayed elution.
- a formulation containing no sorbitol and a formulation of persica gelatin and glycerin, the ratio of which is from 25 parts by mass to 40 parts by mass (preferably (Less than 0 parts by mass) glycerin was preferred, and 30 parts by mass of glycerin was found to be particularly preferred with respect to 100 parts by mass of gelatin.
- sorbitol containing sorbitol which is used in a formulation of sorbitol
- dissolution delay occurs in a long-term stability test.
- the ratio of sorbitol should be less than 30 parts by mass, preferably 20 parts by mass, per 100 parts by mass of gelatin. It was found that the number should be less than one part.
- the present invention can be applied to pharmaceuticals as described below.
- the capsule of the present invention contains (2R) -2-propyloctanoic acid or a salt thereof, it can be used for mammals (for example, humans, non-human animals, for example, monkeys, sheep, horses, horses, Dogs, cats, rabbits, rats, mice, etc.) can be used as preventive and therapeutic agents for various diseases such as neurodegenerative diseases and as Z or symptom progression inhibitors.
- mammals for example, humans, non-human animals, for example, monkeys, sheep, horses, horses, Dogs, cats, rabbits, rats, mice, etc.
- diseases such as neurodegenerative diseases and as Z or symptom progression inhibitors.
- the capsule of the present invention is easily disintegratable in the stomach and has an easy content during chewing. Since it has the property of not leaking, even if the elderly etc. chew by mistake while taking it, it can be taken safely without feeling edami, pain, burning, etc. in the mouth, And it can be absorbed quickly and exhibit pharmacological effects.
- the capsule of the present invention is a soft capsule that is fast-dissolving and has excellent storage stability that can withstand long-term storage without causing dissolution delay. Can exhibit a pharmacological effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0512000-4A BRPI0512000A (pt) | 2004-06-11 | 2005-06-10 | cápsula estável contra mastigação |
MXPA06014396A MXPA06014396A (es) | 2004-06-11 | 2005-06-10 | Capsula estable contra masticacion. |
CA002569746A CA2569746A1 (en) | 2004-06-11 | 2005-06-10 | Capsule stable against mastication |
AU2005251623A AU2005251623A1 (en) | 2004-06-11 | 2005-06-10 | Capsule stable against mastication |
JP2006514617A JP5615478B2 (ja) | 2004-06-11 | 2005-06-10 | 咀嚼に対して安定なカプセル |
US11/629,178 US20080057115A1 (en) | 2004-06-11 | 2005-06-10 | Capsule Stable Against Mastication |
EP05751213A EP1754479A4 (en) | 2004-06-11 | 2005-06-10 | AGAINST CERTAIN STABLE CAPSULE |
RU2006147223/15A RU2384325C2 (ru) | 2004-06-11 | 2005-06-10 | Устойчивая при разжевывании капсула |
NO20065670A NO20065670L (no) | 2004-06-11 | 2006-12-08 | Kapsel som er stabil mot mastikasjon. |
IL179967A IL179967A0 (en) | 2004-06-11 | 2006-12-11 | Capsule stable against mastication |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-174576 | 2004-06-11 | ||
JP2004174576 | 2004-06-11 | ||
JP2005-122821 | 2005-04-20 | ||
JP2005122821 | 2005-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005120490A1 true WO2005120490A1 (ja) | 2005-12-22 |
Family
ID=35502808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/011092 WO2005120490A1 (ja) | 2004-06-11 | 2005-06-10 | 咀嚼に対して安定なカプセル |
Country Status (13)
Country | Link |
---|---|
US (1) | US20080057115A1 (ja) |
EP (1) | EP1754479A4 (ja) |
JP (1) | JP5615478B2 (ja) |
KR (1) | KR20070024722A (ja) |
AU (1) | AU2005251623A1 (ja) |
BR (1) | BRPI0512000A (ja) |
CA (1) | CA2569746A1 (ja) |
IL (1) | IL179967A0 (ja) |
MX (1) | MXPA06014396A (ja) |
NO (1) | NO20065670L (ja) |
RU (1) | RU2384325C2 (ja) |
TW (1) | TW200613009A (ja) |
WO (1) | WO2005120490A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007123153A1 (ja) * | 2006-04-19 | 2007-11-01 | Ono Pharmaceutical Co., Ltd. | 経口投与用カプセル |
JP2014530593A (ja) * | 2011-04-12 | 2014-11-20 | フリト−レイノース アメリカ インコーポレイテッドFrito−Lay North America,Inc. | 香味分のカプセル封入および含水食品のマトリクス介在型濃縮の方法、ならびに該方法から製造される生成物 |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2334295B1 (en) | 2008-09-02 | 2017-06-28 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
EP3278665B1 (en) | 2009-04-29 | 2020-09-09 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
CN108096209A (zh) | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ611606A (en) | 2010-11-29 | 2015-10-30 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US8974594B2 (en) * | 2011-03-29 | 2015-03-10 | Empire Technology Development Llc | Microcapsule corrosion control in reinforced concrete |
US20120251484A1 (en) | 2011-03-31 | 2012-10-04 | Cp Kelco Aps | Cold prepared gel and method for making same |
EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
ITMI20112221A1 (it) * | 2011-12-05 | 2013-06-06 | Altergon Sa | Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio |
AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
KR20150036252A (ko) | 2012-06-29 | 2015-04-07 | 애머린 파마슈티칼스 아일랜드 리미티드 | 스타틴 요법 중인 대상체에서 심혈관 사건의 위험을 감소시키는 방법 |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
WO2014190324A2 (en) | 2013-05-23 | 2014-11-27 | Barlean's Organic Oils, Llc | Rotary die system |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
KR101467853B1 (ko) * | 2014-04-01 | 2014-12-03 | 창성소프트젤 주식회사 | 탄성 및 접착성이 우수하고 얇은 피막으로 생산성과 붕해도가 향상되는 식물성 연질캡슐 및 그의 조성물과 그 제조방법 |
US20150335586A1 (en) * | 2014-05-20 | 2015-11-26 | R.P. Scherer Technologies, Llc | Capsule dispensing container |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
EP3212152A4 (en) | 2014-10-31 | 2018-11-07 | Barlean's Organic Oils, LLC | Method and apparatus for the manufacture of softgels |
KR101655407B1 (ko) * | 2015-09-02 | 2016-09-08 | 주식회사 아미코스메틱 | 마이크로 캡슐, 및 마이크로 캡슐을 포함하는 화장료 조성물 |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
MX2017016719A (es) * | 2017-12-19 | 2020-01-20 | Alepharma Soc Anonima Promotora De Inversion De Capital Variable | Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada. |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
EP3750536A1 (en) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
KR102412895B1 (ko) | 2020-03-03 | 2022-07-06 | 주식회사 휴온스메디컬 | 시린지의 플런저 고정장치 |
CN114983962B (zh) * | 2021-03-02 | 2024-03-15 | 仙乐健康科技股份有限公司 | 软胶囊囊壳组合物、软胶囊和其制备方法和用途 |
US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0565222A (ja) * | 1991-09-09 | 1993-03-19 | Fuji Capsule Kk | カプセル剤用プルラン配合皮膜及びカプセル剤 |
JP2002097158A (ja) * | 2000-07-18 | 2002-04-02 | Ono Pharmaceut Co Ltd | アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3173840A (en) * | 1962-04-30 | 1965-03-16 | Lilly Co Eli | Separation-resistant capsule |
US3927195A (en) * | 1974-01-31 | 1975-12-16 | Lilly Industries Ltd | Production of capsules |
JPH089536B2 (ja) * | 1987-10-30 | 1996-01-31 | 日清製粉株式会社 | 腸溶性カプセルの製造方法 |
US4954346A (en) * | 1988-06-08 | 1990-09-04 | Ciba-Geigy Corporation | Orally administrable nifedipine solution in a solid light resistant dosage form |
JPH04288011A (ja) * | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | 軟カプセル剤 |
KR20050071718A (ko) * | 1996-07-12 | 2005-07-07 | 다이이찌 세이야꾸 가부시기가이샤 | 속붕괴성 압축성형물 및 그의 제조법 |
JP3261331B2 (ja) * | 1997-03-31 | 2002-02-25 | 東海カプセル株式会社 | 咀嚼用ソフトカプセル剤 |
JP2000128778A (ja) * | 1998-10-20 | 2000-05-09 | Tokai Capsule Kk | 捩じり切り開披型ソフトカプセル |
KR100759771B1 (ko) * | 2000-07-18 | 2007-10-04 | 오노 야꾸힝 고교 가부시키가이샤 | 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제 |
KR20040016991A (ko) * | 2001-07-18 | 2004-02-25 | 오노 야꾸힝 고교 가부시키가이샤 | 뇌허혈 질환 치료제 |
US20050058703A1 (en) * | 2003-08-01 | 2005-03-17 | Chang Robert C. | Gelatin capsules |
US8053599B2 (en) * | 2003-10-03 | 2011-11-08 | Ono Pharmaceutical Co., Ltd. | Drug containing (2R)-2-propyloctanoic acid as the active ingredient |
-
2005
- 2005-06-09 TW TW094119016A patent/TW200613009A/zh unknown
- 2005-06-10 CA CA002569746A patent/CA2569746A1/en not_active Abandoned
- 2005-06-10 MX MXPA06014396A patent/MXPA06014396A/es not_active Application Discontinuation
- 2005-06-10 RU RU2006147223/15A patent/RU2384325C2/ru not_active IP Right Cessation
- 2005-06-10 EP EP05751213A patent/EP1754479A4/en not_active Withdrawn
- 2005-06-10 KR KR1020077000705A patent/KR20070024722A/ko not_active Application Discontinuation
- 2005-06-10 AU AU2005251623A patent/AU2005251623A1/en not_active Abandoned
- 2005-06-10 BR BRPI0512000-4A patent/BRPI0512000A/pt not_active IP Right Cessation
- 2005-06-10 WO PCT/JP2005/011092 patent/WO2005120490A1/ja active Application Filing
- 2005-06-10 US US11/629,178 patent/US20080057115A1/en not_active Abandoned
- 2005-06-10 JP JP2006514617A patent/JP5615478B2/ja not_active Expired - Fee Related
-
2006
- 2006-12-08 NO NO20065670A patent/NO20065670L/no not_active Application Discontinuation
- 2006-12-11 IL IL179967A patent/IL179967A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0565222A (ja) * | 1991-09-09 | 1993-03-19 | Fuji Capsule Kk | カプセル剤用プルラン配合皮膜及びカプセル剤 |
JP2002097158A (ja) * | 2000-07-18 | 2002-04-02 | Ono Pharmaceut Co Ltd | アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1754479A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007123153A1 (ja) * | 2006-04-19 | 2007-11-01 | Ono Pharmaceutical Co., Ltd. | 経口投与用カプセル |
JP2014530593A (ja) * | 2011-04-12 | 2014-11-20 | フリト−レイノース アメリカ インコーポレイテッドFrito−Lay North America,Inc. | 香味分のカプセル封入および含水食品のマトリクス介在型濃縮の方法、ならびに該方法から製造される生成物 |
Also Published As
Publication number | Publication date |
---|---|
RU2006147223A (ru) | 2008-07-20 |
EP1754479A1 (en) | 2007-02-21 |
RU2384325C2 (ru) | 2010-03-20 |
NO20065670L (no) | 2007-03-12 |
US20080057115A1 (en) | 2008-03-06 |
IL179967A0 (en) | 2007-05-15 |
JPWO2005120490A1 (ja) | 2008-04-03 |
MXPA06014396A (es) | 2007-03-12 |
TW200613009A (en) | 2006-05-01 |
KR20070024722A (ko) | 2007-03-02 |
JP5615478B2 (ja) | 2014-10-29 |
BRPI0512000A (pt) | 2008-01-22 |
AU2005251623A1 (en) | 2005-12-22 |
EP1754479A4 (en) | 2011-03-23 |
CA2569746A1 (en) | 2005-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5615478B2 (ja) | 咀嚼に対して安定なカプセル | |
US10342763B2 (en) | Chewable soft capsules | |
JP5777170B2 (ja) | 速溶性固体剤形 | |
JP6113954B2 (ja) | 医薬として使用するための脂肪酸 | |
WO2007055327A1 (ja) | ゼリー組成物 | |
EP1587497A1 (de) | Verfahren zur herstellung einer oralen arzneiform mit unmittelbarem zerfall und wirkstofffreisetzung | |
IE56058B1 (en) | New oral mopidamol preparations | |
JP6664080B2 (ja) | プレガバリン徐放性製剤 | |
Higton | The pharmaceutics of ibuprofen | |
JP2015533367A (ja) | S−アデノシルメチオニンおよび没食子酸エステルを含む組成物 | |
KR100732199B1 (ko) | 저작성 캡슐 및 그 제조 방법 | |
KR20090086128A (ko) | 메만틴 약학 조성물 | |
US9155704B1 (en) | More palatable, bioequivalent pharmaceutical composition of carprofen | |
US9314435B2 (en) | Stable formulations of antiplatelet agents, omega-3 fatty acids and amylose in soft gelatin capsules | |
JP2018500278A (ja) | 外部粘膜に適用する剤形物品 | |
CN101001622A (zh) | 对于咀嚼稳定的胶囊 | |
JP2006514672A (ja) | 疎水性物質を徐放剤として含有する制御性放出製剤 | |
WO2007123153A1 (ja) | 経口投与用カプセル |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006514617 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2569746 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2005751213 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005751213 Country of ref document: EP Ref document number: 551901 Country of ref document: NZ Ref document number: 2006/10307 Country of ref document: ZA Ref document number: PA/a/2006/014396 Country of ref document: MX Ref document number: 200610307 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 179967 Country of ref document: IL Ref document number: 11629178 Country of ref document: US Ref document number: 4534/CHENP/2006 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005251623 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005251623 Country of ref document: AU Date of ref document: 20050610 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006147223 Country of ref document: RU Ref document number: 1020077000705 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005251623 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580027281.9 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005751213 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020077000705 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0512000 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 11629178 Country of ref document: US |